^
    Back
    Association details:
    Biomarker:PD-L1 overexpression + KRAS G12C + TP53 mutation
    Cancer:Lung Non-Squamous Non-Small Cell Cancer
    Drug:Keytruda (pembrolizumab) (PD1 inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C3 – Early Trials
    New
    Source:
    J Thorac Oncol
    Title:

    Outcome of first-line treatment with pembrolizumab according to KRAS/TP53 mutational status for non-squamous PD-L1 high (≥50%) NSCLC in the German National Network Genomic Medicine Lung Cancer (nNGM)

    Published date:
    12/15/2023
    Excerpt:
    696 consecutive patients with PD-L1 high (≥50%), non-squamous NSCLC, having received molecular testing within the German National Network Genomic Medicine Lung Cancer between 2017 and 2020, with ECOG-PS ≤1 and pembrolizumab as first-line palliative treatment were included into this retrospective cohort analysis....G12C/TP53mut patients experienced the longest PFS and OS (33.7 and 65.3 months)...
    DOI:
    10.1016/j.jtho.2023.12.015